TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines up

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, includi

Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus

Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million

Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analy

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its inducement awards granted for July 20

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely ea

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Augu

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook b

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,

Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven p

Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.

Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Est

Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Yea

Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Yea

Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analy

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology hosted a conference call and provided a corporate u

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to six new hires

Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. P

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,

Puma Biotechnology, Inc. (NASDAQ: PBYI - Get Free Report) shares passed above its 200-day moving ave

Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000 million-$221.000 million vs $220.000

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.29 per share which beat the analy

Puma Biotechnology (NASDAQ:PBYI) sees Q1 sales of $38.000 million-$42.000 million vs $49.000 million

Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000-$221.000 million vs $220.000 million

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.30 per share which beat the analy

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been add

Puma Biotechnology (NASDAQ:PBYI) raises FY2025 sales outlook from $212.000 million-$222.000 million

Puma Biotechnology (NASDAQ:PBYI) sees Q4 sales of $67.000 million-$70.000 million vs $66.600 million

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.21 per share which beat the analy

Puma Biotechnology (NASDAQ:PBYI) affirms FY2025 sales outlook from $212.000 million-$222.000 million

Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $48.000 million-$51.000 million vs $60.000 million

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.15 per share which beat the analy

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.10 per share which beat the analy

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a B

Puma Biotechnology (NASDAQ:PBYI) sees Q1 sales of $42.500 million-$45.500 million vs $47.50 million